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S U M M A R Y
Background: The prevalence of multidrug-resistant tuberculosis (TB) among new and retreatment cases
in 2011 in Ethiopia was 2.7% and 17.9%, respectively. However, data on heteroresistance and gene
mutation proﬁles of Mycobacterium tuberculosis were not documented.
Methods: A cross-sectional study was conducted on 413 TB-positive clinical specimens submitted
between 2012 and 2014 to Bahir Dar Regional Laboratory Center for conﬁrmation of multidrug
resistance. Resistance determining genes were analyzed using a line probe assay.
Results: Of 413 M. tuberculosis isolates, 150 (36.3%) were multidrug-resistant, 19 (4.6%) were resistant
only to rifampicin, and 26 (6.3%) were resistant to isoniazid. Of 169 rifampicin-resistant and
176 isoniazid-resistant isolates, only eight (4.7%) showed rifampicin heteroresistance and only two
(1.13%) showed isoniazid heteroresistance. Failing of the rpoB WT8 gene with corresponding
hybridization of rpoB MUT3 (S531L substitution) accounted for 85 (50.3%) rifampicin-resistant
mutations. Among 176 isoniazid-resistant isolates, 155 (88.1%) strains had the Ser315Thr1 substitution.
Conclusions: The prevalence of multidrug-resistant M. tuberculosis was high in the study area. Ser531Leu
and Ser315Thr1 substitutions were the highest gene mutations for rifampicin and isoniazid,
respectively.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Multidrug-resistant tuberculosis (MDR-TB) is caused by strains
of Mycobacterium tuberculosis that are resistant to isoniazid (INH)
and rifampicin (RMP).1,2 Despite the availability of highly efﬁcacious
treatment for decades, tuberculosis (TB) remains a major global
health problem.1,3–5 Globally, 3.5% of MDR-TB has been reported in
new TB cases and 20.5% in previously treated TB cases.6,7 In Ethiopia
in 2011, the prevalence of MDR-TB among new and retreatment
cases was reported to be 2.7% and 17.9%, respectively.8
An erratic drug supply, suboptimal physician prescription, poor
patient adherence,9 initial high bacterial population, and mono-
therapy have been associated with the emergence of resistance.10* Corresponding author. Tel.: +251 912 99 02 88.
E-mail address: nigusdaniel@gmail.com (D. Mekonnen).
http://dx.doi.org/10.1016/j.ijid.2015.06.013
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Some patients with TB harbor mixed populations of drug-
susceptible and resistant organisms, a phenomenon that is referred
to as heteroresistance. Therefore, heteroresistant strains are
precursors for full resistance.11
The genetic background of M. tuberculosis related to INH
resistance is complex. However, mutations in several genes,
including katG (catalase peroxidase coding genes),12 ahpC, inhA,
kasA, and ndh, have all been associated with INH resistance.10,13,14
Between 50% and 95% of INH-resistant strains contain mutations in
codon 315 of the katG gene.9 Furthermore, 20% and 35% of INH-
resistant strains contain mutations in the inhA regulatory
region.13,14 The most common inhA mutation occurs in its
promoter region (C15T) and this is frequently associated with
monoresistance.13,14 Strains bearing mutations in the coding
region of inhA show low-level resistance.10,15
Mutations in the RNA polymerase b subunit (rpoB) gene have
been found in about 96% of RMP-resistant M. tuberculosisciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
D. Mekonnen et al. / International Journal of Infectious Diseases 39 (2015) 34–38 35isolates.14–16 Mutations in codons 531 and 526 are the most
frequently reported mutations.14–16
Information on the current prevalence of MDR-TB, hetero-
resistance, and drug resistance mutations has not been documen-
ted in Amhara National Regional State (ANRS), Ethiopia. This study
was conducted to determine the prevalence of MDR-TB, hetero-
resistance, and gene mutations to RMP and INH among presump-
tive MDR-TB cases in ANRS, Ethiopia.
2. Materials and methods
2.1. Study design and sampling technique
A cross-sectional study was conducted between May 2012 and
February 2014. During the study period, 856 presumptive MDR-TB
cases (sputum and extrapulmonary (peritoneal ﬂuid, tissue, lymph
node aspirate, and pus specimens)) were referred to the Bahir Dar
Regional Health Research Laboratory Center (BRHRLC). However,
only 413 (48.2%) of these clinical samples were TB-positive. This
study included the 413 M. tuberculosis isolates for gene mutation
analysis.
2.2. Specimen processing
The clinical samples were processed using the N-acetyl-L-
cysteine NaOH (NALC-NaOH) method. The processed samples
were suspended in 1.0 ml sterile phosphate buffer (pH 7.0) and
then 100 ml of resuspended pellet was inoculated onto
two Lowenstein–Jensen (LJ) medium slants. Smears for micro-
scopic examination were stained using the Ziehl–Neelsen (ZN)
method.
DNA was extracted from samples that were smear- and/or
culture-positive using GenoLyse chemical methods. From the
extracted DNA, 5 ml was used directly for PCR ampliﬁcation.
Master mix preparation, DNA addition, ampliﬁcation, hybridiza-
tion, and interpretation were performed as recommended by the
manufacturer (Hain Lifescience GmbH, Nehren, Germany).13,17Figure 1. Line probe assay strips showing controls and rifampicin (RMP) andResistance determining genes were analyzed using a line probe
assay (LPA).
2.3. LPA interpretation
Susceptibility to anti-TB drugs was deﬁned as hybridization
(presence of a band) to all the wild-type (WT) probes and no
hybridization (absence of a band) to the mutant probes. The
absence of hybridization of any WT and/or hybridization of any
mutant gene indicates resistance to the respective drugs.
Hybridization of WT and mutant genes indicates heteroresistance
or a mixed infection (Figure 1).
2.4. Statistical analysis
All data were entered, cleared, and analyzed using IBM SPSS
Statistics for Windows, version 20.0 (IBM Corp. Armonk, NY, USA).
Descriptive statistics were used to visualize differences within the
data. Binary logistic regression was used to assess possible factors
associated with MDR-TB and heteroresistance. Gene mutations
were analyzed manually.
2.5. Data quality assurance
DNA extraction positive (H37Rv) and negative controls and
master mix controls were used. Fifty isolates were characterized at
the national TB laboratory using the BACTEC MGIT (Mycobacteria
Growth Indicator Tube) 960 TB system (BD Diagnostics, USA). Lot-
to lot quality assurance systems were in place to verify the quality
of the commercial kit. All procedures were done using standard
operating procedures.
2.6. Ethical considerations
Ethical clearance was obtained from the Amhara Regional
Health Bureau Research Ethics Review Committee and ofﬁcial
permission was obtained from BRHRLC. isoniazid (INH) resistance-associated banding patterns; Ethiopia, 2015.
Table 1
Demographic characteristics and proﬁle of presumptive MDR-TB cases (N = 413);
Ethiopia, 2015
Variables Number Percentage
Sex Male 229 55.4
Female 184 44.6




TB history New cases 71 17.2
Retreatment cases 342 82.8






MDR, multidrug-resistant; TB, tuberculosis.
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3.1. Multidrug-resistant tuberculosis
A total of 413 TB-positive patients were included in the study.
Of these, 229 (55.4%) were males. The mean age of participants was
34.5 years and 211 (51.1%) were in the 19–34 years age group.
Moreover, 342 (82.8%) patients were retreatment TB cases and 71
(17.2%) were newly identiﬁed TB cases. With regard to their TB
history, 160 (38.7%) were relapse cases, 132 (32%) were failure
cases, and 32 (7.7%) were defaulters (Table 1).Table 2
Frequency and pattern of rpoB, katG, and inhA mutations of Mycobacterium tuberculosis









MDR (n = 150)
WT2 and 3 No 510–513 WT MUT1 
WT2, 3, and 4 Unknown 510–520 WT MUT1 
WT3 and 4 Unknown 513–519 WT MUT1 
WT3 Unknown 514–515 WT MUT1 
WT2 No 511–512 No No 
WT7 MUT2A H526Y WT MUT1 
WT7 MUT2B H526D WT MUT1 
WT7 Unknown 526 WT MUT1 
WT8 MUT3 S531L WT MUT1 
WT8 Unknown 531–533 WT MUT1 
WT8 MUT3 S531L WT No 
WT8 MUT3 S531L No No 
WT8 MUT3 S531L WT MUT1 
WT8 MUT3 S531L WT MUT2 
WT8 Unknown 531–533 WT No 
RMP-MR (n = 19)
WT7 MUT2A H526Y No No 
WT7 MUT2B H526D No No 
No MUT2A H526Y No No 
WT8 MUT3 S531L No No 
WT8 Unknown 531–533 No No 
INH-MR (n = 26)
No No No WT MUT1 
No No No WT No 
No No No No No 
C, cysteine; D, aspartate; Dele, Deletion; H, histidine; INH, isoniazid; L, leucine; LPA, lin
rifampicin; S, serine; T, threonine; WT, wild-type; Y, tyrosine.
No = no failing of the WT gene, or no appearance of mutant gene; Unknown = there were 
a One patient had RMP heteroresistance.
b One patient had INH heteroresistance.
c Five patients had RMP heteroresistance.Of the 413 M. tuberculosis cases, 150 (36.3%) were MDR-TB
(RMP+INH), 19 (4.6%) were resistant only to RMP, and 26 (6.3%)
were resistant to INH.
Considering possible associated variables such as gender, age,
type of TB, and history of TB treatment, none was signiﬁcantly
associated with MDR-TB or with RMP or INH resistance (data not
shown).
3.2. Heteroresistance
Of 169 RMP-resistant and 176 INH-resistant M. tuberculosis
isolates, eight (4.7%) showed RMP heteroresistance and two
(1.13%) showed INH heteroresistance. The possible variables such
as gender, age, type of TB, and history of TB treatment were not
signiﬁcantly associated with heteroresistance (data not shown).
3.3. RMP and INH resistance-associated gene mutations
Of the 413 isolates, 169 (40.9%) were resistant to RMP. Failing of
the rpoB WT8 gene with corresponding hybridization of rpoB MUT3
(Ser531Leu substitution) accounted for 85 (50.3%) mutations.
Moreover, failing of WT7 with the appearance of mutants 2A and
2B (H526Y and H526D substitutions, respectively) shared 14.8% of
RMP-resistant gene mutation. There was no failing of the rpoB
WT1, 5, or 6 genes and no hybridization of the rpoB MUT1 probe
(Table 2).
Of 176 INH-resistant strains, 155 (88.1%) were due to failing of
the katG WT gene with hybridization of the katG MUT probe
(Ser315Thr1 substitution). Of the rest, ﬁve (2.8%) were due to
failing at the inhA WT1 gene (C15T substitution). Moreover, three; Ethiopia, 2015









S315T1 No No No 9 (6)
S315T1 No No No 3 (2)
S315T1 No No No 20 (13.3)
S315T1 No No No 1 (0.67)
No WT1 MUT1 C15T 1 (0.67)
S315T1 No No No 14 (9.3)a
S315T1 No No No 5 (3.3)b
S315T1 No No No 14 (9.3)
S315T1 No No No 60 (40)c
S315T1 No No No 6 (4)
Dele, 315 No No No 11 (7.3)a
No WT1 MUT1 C15T 1 (0.67)
S315T1 WT1 MUT1 C15T 3 (2)b
S315T2 No No No 1 (0.67)
Dele, 315 No No No 1 (0.67)
No No No No 4 (21)
No No No No 2 (10.5)
No No No No 1 (5.3)a
No No No No 9 (47.4)
No No No No 3 (15.8)
S315T1 No No No 19 (73.1)
Dele, 315 No No No 4 (15.4)
No WT1 MUT1 C15T 3 (11.5)
e probe assay; MDR, multidrug-resistant; MR, Monoresistant; MUT, mutant; RMP,
two or more mutant genes but the LPA did not have a probe for these mutant genes.
Figure 2. Line probe assay strips showing the heteroresistant population of Mycobacterium tuberculosis; Ethiopia, 2015.
Source: Barnard M, Parsons L, Miotto P, Cirillo D, Feldmann K, Gutierrez C, Somoskovi A. Molecular detection of drug-resistant tuberculosis by line probe assay. Laboratory
manual for resource-limited settings (http://www.ﬁnddiagnostics.org).
D. Mekonnen et al. / International Journal of Infectious Diseases 39 (2015) 34–38 37(1.7%) INH resistance cases were due to mutations from both
Ser315Thr1 and C15T substitutions (Table 2).
Based on gene mutation analysis, 60 (40%) MDR cases were due
to Ser531Leu:Ser315Thr1 substitution. Moreover, the combination
mutation of failing at WT3, 4 of RMP and Ser315Thr1 substitution
of INH accounted for 20 (13.3%) MDR-TB. H526Y and Ser315Thr1
substitutions were MDR-TB mutations in 14 (9.3%) (Table 2). Out of
26 cases of RMP monoresistance, nine (47.4%) were due to
Ser531Leu substitution and four (21%) to H526Y substitution.
Nineteen (73.1%) of the INH monoresistance cases were due to




This study showed that MDR-TB is a serious public health
problem in Ethiopia. A high prevalence of MDR-TB with lower
heteroresistance might indicate a high transmission rate of
primary resistant TB in this area.
The prevalence of MDR-TB in this study was higher than the
drug resistance survey in Ethiopia.8 The reason for this might be
differences in study population; the present study population
comprised presumptive MDR-TB cases, but the Ethiopia drug
resistance survey involved smear-positive TB cases. Furthermore,
the prevalence is higher than those reported from Germany (4%),
Iran (12.2%), China (5.6%), in World Health Organization (WHO)
reports, and Swaziland.7,18–22 The reason for this might again be
differences in study population, but might also be related to the
time of the study, geography, and methodological differences.
4.2. Heteroresistance
The prevalence of RMP heteroresistance (mixed infection) was
1.9% (n = 8). Only two (0.5%) cases of INH heteroresistance were
detected in this study. The proportion of heteroresistance in this
study is lower than that reported in studies conducted in
Uzbekistan and India.23,24 This discrepancy might be the results
of several factors. For instance, the prevalence of TB and MDR-TB
might inﬂuence the occurrence of heteroresistance, like in India.25A high TB incidence certainly increases the risk of superinfection.
Furthermore, differences in the source of isolates (direct specimen,
culture) and typing methods has resulted in differences in
detecting heteroresistance.25
These heteroresistant populations of bacteria might occur
during a chronic infection, because several subpopulations may
coexist in the same patient with different drug susceptibility
proﬁles.22 Heteroresistance may develop during treatment or by
mixed/superinfection with sensitive and resistant strains.26 The
LPA is capable of detecting the presence of heteroresistance since
the strips contain both WT and mutant probes (Figure 2A: bands
12 and 16).
4.3. RMP and INH resistance-associated gene mutations
The assessment of gene mutations showed that codon 531 of
the rpoB gene and codon 315 of the katG gene accounted for 50.3%
and 88.1% of RMP and INH resistance, respectively. This ﬁnding is
in agreement with those of studies done in China, Sweden, Turkey,
Ethiopia, and India.15,27–30 However, the level of Ser531Leu
substitution was lower than reported in studies done in Brazil,
Pakistan, China, and Nepal.31–34 This might be due to differences in
the strain and lineage of isolates. The mutation frequency of INH
resistance due to C15T substitution in this study was 1.9% (n = 8);
however, studies done in Pakistan, China, and Nepal have shown a
higher prevalence of C15T substitution.32–34This study showed a
high prevalence of MDR-TB and a lower prevalence of hetero-
resistant M. tuberculosis. Ser531Leu and Ser315Thr1 substitutions
were the highest gene mutations for rifampicin and isoniazid,
respectively.
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